Results showed that the baseline CD8+ T‐cell density in responders was higher than in nonresponders.34 In a Phase 2 study of ipilimumab in metastatic melanoma, however, baseline TIL status was not related to clinical effects.35 Instead, the increase in TIL density in tumor biopsy specimens obtained after the second course of treatment with ipilimumab showed a positive association with clinical effects. Here, CD8A is linked to neoplasm.